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Abstract Like many eicosanoids, epoxyeicosatrienoic
acids (EETs) have multiple biological functions, including
reduction of blood pressure, inflammation, and atheroscle-
rosis in multiple species. Hydration of EETs by the soluble
epoxide hydrolase (sEH) is the major route of their
degradation to the less bioactive diols. Inhibition of the
sEH stabilizes EETs, thus, enhancing the beneficial effects
of EETs. Human data show an association of sEH (Ephx2)
gene polymorphisms with increased risk of atherosclerosis
and cardiovascular diseases. These data suggest a potential
therapeutic effect of sEH inhibitors (sEHI) in the treatment of
atherosclerosis. Indeed, two laboratories reported indepen-
dentlythatusingdifferentsEHIsinapolipoproteinE–deficient
micesignificantly attenuatedatherosclerosis development and
aneurysm formation. The antiatherosclerotic effects of sEHI
arecorrelatedwithelevationinEETlevelsandassociatedwith
reduction of low-density lipoprotein and elevation of high-
density lipoprotein cholesterols, as well as attenuation of
expression of proinflammatory genes and proteins. In addi-
tion, the antihypertensive effects and improvement of endo-
thelial function also contribute to the mechanism of the
antiatherosclerotic effects of sEHI. The broad spectrum of
biological action of EETs and sEHIs with multiple biological
beneficial actions provides a promising new class of thera-
peutics for atherosclerosis and other cardiovascular diseases.
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Introduction
Atherosclerosis is a chronic vascular inflammatory disease
characterized by chronic inflammation and abnormalities in
cholesterol transport leading to foam cell and plaque
formation in the arterial wall. It is a major cause of cardiac
death with several life-threatening cardiovascular compli-
cations, including myocardial infarction and stroke when
the atherosclerotic plaque ruptures. Currently, the major
pharmacologic intervention for atherosclerosis is to use
statins alone or in combination with niacin and fibrates to
lower low-density lipoprotein (LDL) and to increase high-
density lipoprotein (HDL), in addition to modifications in
diet. Statins inhibit 3-hydroxy-3-methylglutaryl coenzyme
A (HMG-CoA) reductase, the rate-limiting enzyme in
cholesterol synthesis, and increase LDL cholesterol
clearance. Statins have been shown to be effective in
reducing cholesterol and attenuation of atherosclerosis
and cardiovascular risk in patients. Moreover, a new-
generation statin, namely rosuvastatin, has been shown to
attenuate coronary atherosclerosis [1]. In this clinical
trial, known as A Study to Evaluate the Effect of
Rosuvastatin on Intravascular Ultrasound-Derived Coro-
nary Atheroma Burden (ASTEROID), high-intensity
rosuvastatin therapy not only dramatically decreased
LDL cholesterol, but also attenuated atherosclerotic
plaques in the coronary arteries [1]. Anti-inflammatory
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DOI 10.1007/s11883-010-0108-5drugs, such as low-dose aspirin, and antihypertensive drugs,
in particular angiotensin-converting enzyme inhibitors and
angiotensin receptor blockers, also have beneficial effects in
the prevention of atherosclerosis and reducing the cardio-
vascular risk when used prophylactically or in combination
with statins.
Several key enzymes and receptors in the arachidonic
acid (AA) cascade are important targets for atherosclerosis
[2]. A novel target is the soluble epoxide hydrolase (sEH).
A major function of the sEH is to metabolize the epoxides
of AA and linoleic acid that are the regioisomers of
epoxyeicosatrienoic acids (EETs) and epoxyoctadecenoic
acids (EpOMEs) to their corresponding diols, dihydroxyei-
cosatrienoic acid (DHET) and dihydroxyoctadecenoic acid
(DiHOME), respectively. The epoxides of AA, EETs have
protective effects on the vasculature, kidney, and the heart.
Inhibitors of sEH reduce inflammation and prevent the
development of atherosclerotic plaques, presumably via an
increase in EETs and other epoxy lipids, as well as a
decrease in the corresponding diols [3••, 4••].
The purpose of this review is to discuss the role of EETs
and sEH in the pathogenesis of atherosclerosis as well as
the preclinical and clinical evidence that supports the
rationale to use sEHI as therapeutics for prevention and
treatment of atherosclerosis and its complications.
Biological Activities of EETs and sEH and Potential
Therapeutic Applications
AA can be metabolized by three major oxidative pathways:
cyclooxygenase (COX), forming prostaglandins and related
eicosanoids; lipoxygenase (LOX), forming leukotrienes and
related compounds; and cytochrome P450 (CYP450)
monooxygenase, forming epoxides and alcohols such as
20-HETE (Fig. 1). The COX and LOX pathways have been
investigated extensively, and their eicosanoid products have
been shown to play important roles in a variety of
biological processes such as inflammation, cell prolifera-
tion, and intracellular signaling. However, the less studied
“third pathway” of the AA cascade involving CYP450
enzymes is receiving increasing attention. EETs are
synthesized from AA by oxidation reactions catalyzed by
CYP450s. These regulatory lipid molecules have multiple
biological functions, among which vasorelaxation has been
studied most extensively. EETs and other bioactive fatty
acid epoxides are formed in endothelial cells via stimulation
of AA release from phospholipids and communicate with
vascular smooth muscle cells (VSMC) through large
conductance Ca
2+ activated K (BK) channels via a putative
G-protein–coupled receptor that signals via Gsα [5],
leading to membrane hyperpolarization, hence causing
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LOX
P450 2C/2J
sEH
P450 4A/4F
Fig. 1 The arachidonic acid
(AA) cascade. AA is metabo-
lized by three major oxidative
pathways: 1) cyclooxygenase
(COX), forming prostaglandins
and related eicosanoids; 2)
lipoxygenase (LOX), forming
leukotrienes and related com-
pounds; and 3) CYP450, form-
ing epoxides (2C/2J) and
20-HETEs (4A/4F). Epoxyeico-
satrienoic acids (EET)s are vas-
odilatory and anti-inflammatory,
whereas 20-HETE antagonizes
these effects of EETs. Soluble
epoxide hydrolase (sEH)
degrades EETs to their less
bioactive corresponding
dihydroxyeicosatrienoic acid
(DHETs), thereby reducing
beneficial effects of EETs.
Inhibitors of sEH stabilize EETs,
and prolong the duration of
action of EETs, thus, enhancing
the effects of reducing hyper-
tension, inflammation, and pain
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endothelium-derived hyperpolarizing factors (EDHFs) [6].
The EDHF effects of EETs dominate in microvessels and are
independent of nitric oxide (NO) and prostacyclin (PGI2),
which mainly act on conduit vessels. In the renal microcir-
culation, EETs contribute to vasorelaxation (leading to
regulation of renal blood flow) and to ion transport (leading
to inhibition of sodium reabsorption), thereby contributing to
blood pressure lowering [7]. On the contrary, another
CYP450 metabolite in the AA cascade, 20-HETE, has been
shown to partially antagonize the effects of EETs by acting
as a BK channel antagonist in the renal microcirculation,
thereby increasing blood pressure [8].
These biochemically short-lived EETs are quickly
degraded by sEH into their corresponding diols or DHETs,
which generally are less bioactive. The sEH thus reduces
the beneficial effects of EETs [9]. Epoxide hydration is the
dominant pathway of EETs degradation, but EETs are also
metabolized by β oxidation, chain elongation, hydroxyl-
ation, incorporation into the cell membrane phospholipids,
and/or even via other enzymes in the arachidonate cascade
[10]. Early sEH inhibitors were competitive substrates or
substrates that were slowly turned over. These compounds
were of limited use in vivo. The first transition state mimic
inhibitors potent enough for in vivo use were based on urea,
carbamate, and amide pharmacophores [9, 11]. Inhibitors of
sEH can enhance these effects by stabilizing EETs and
other lipid epoxides and by reducing some proinflammatory
diols [12]. Thus, inhibition of sEH has been proposed as a
therapeutic target to treat hypertension and its complica-
tions [13]. Indeed, a variety of sEH inhibitors have been
shown to decrease blood pressure in a number of rodent
models of hypertension [7, 14, 15]. In addition to vaso-
relaxation, EETs have also been shown to be anti-
inflammatory, analgesic, and mildly angiogenic [7, 10].
The efficacy of sEH inhibitors has been demonstrated in
animal models to reduce cardiac hypertrophy [16], attenu-
ate sepsis-induced inflammation [12], and decrease inflam-
matory pain [17]. The biological effects seen in these
studies can be attributed to inhibition of sEH activity
evidenced by an increase in plasma EET to DHET ratio.
Furthermore, sEH is widely expressed in the liver, kidney,
heart, brain, and other tissues; thus the anti-inflammatory
effects of sEHI offer novel treatment options in a range of
disease models, including atherosclerosis, pain, stroke, and
diabetes [3••, 4••, 17–20].
sEHIs have been shown to reverse cardiac hypertrophy
in several animal models. In a mouse model of angiotensin
II (Ang II)-induced cardiac hypertrophy, treatment with a
potent sEHI, 1-(1-methanesulfonyl-piperidin-4-yl)-3-(4-
trifluoromethoxy-phenyl)-urea (TUPS),significantlyreduced
cardiac hypertrophy and improved cardiac contractility [21].
The in vitro experiment in neonatal cardiac myocytes treated
with Ang II revealed that the antihypertrophic effect of sEHI
is concentration dependent and associates with downregula-
tion of COX-2 via an increase in the ratio of EET to DHET,
indicating that antihypertrophic efficacy of sEHI acts directly
on cardiomyocytes, independent of blood pressure regulation
[22]. In a murine model of cardiac hypertrophy induced by
thoracic aortic banding (TAC), the sEHI blocked nuclear
factor–κB( N F - κB) activation, thereby reducing inflamma-
tion, and decreased the gene expression of the cardiac
hypertrophy markers, including atrial natriuretic factor,
skeletal actin, and major histocompatibility complex
(MHC), compared with that in vehicle control group [22].
Later on, more insight in the role of sEH in cardiac
hypertrophy came with another study in two different rat
models: spontaneously hypertensive rats (SHRs) and Ang II-
infused Wistar rats [16]. This study revealed that Ang II
dose-dependently upregulated cardiac sEH expression in-
volving AP-1 transcription factor activation, which could be
reversed by losartan, an angiotensin type 1 (AT-1) receptor
antagonist. In a murine model of coronary artery ligation,
sEHIs are also found to be protective against heart failure
and cardiac arrhythmias after myocardial infarct by reducing
infarct size and preventing cardiac remodeling [23]. In this
study, at 3 weeks after ligation, the ratios of EET to DHET
and EpOME to DiHOME were increased, along with a
decrease in cytokines in the sEHI-treated compared with the
sEHI-untreated group. Because the sEHI had cardioprotec-
tive effects in variety animal models of cardiac hypertrophy
and heart failure, including non–Ang II-induced models,
multiple mechanisms may be involved in the mode of action.
sEH Polymorphism and Atherosclerosis
sEH is expressed in many organisms, including plants,
nematodes, and humans. It was reported in the 1970s that
laboratory rats have by far the lowest levels of hepatic sEH
among the mammals studied. Increased sEH gene expres-
sion and activity along with renal eicosanoid metabolism
have been reported to participate in the pathogenesis of
hypertension in SHRs [14]. It has been observed in many
laboratories that increased sEH is associated with a
lowering of blood pressure in several but not all strains of
SHR [24, 25]. Investigating the role of sEH in hypertensive
animals, Fornage et al. [26] reported that sub-strains of
SHR and its wild-type control WKY rats obtained from
different sources (eg, Heidelberg vs Charles River) show
differences in the level of Ephx2 (sEH) gene expression,
activity, and protein abundance. In order to understand the
underlying mechanisms of differences in sEH in these rat
strains, the authors hypothesized that single nucleotide
polymorphisms (SNPs) may be responsible for the differ-
ences in sEH as well as blood pressure in these animals.
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and WKY revealed four SNPs, which create two Ephx2
alleles. These variants included G405A, G560A, C780T,
and G1465A (NCBI NM_022936, reference sequence). The
SHR Heidelberg sequence was found to be identical to that
of Sprague-Dawley rats.
The homozygous ancestral alleles were identified to be
present in the SHR (Heidelberg) and WKY (Charles River),
whereas the variant alleles were identified in the SHR
(Charles River) and WKY (Heidelberg) strains. A strong
correlation was found between the inheritance of these alleles
and the gene expression, protein abundance (confirmed by
semi-quantitative Western blot analysis), and sEH activity (in
renal cortex) but not blood pressure in the F2 progeny
obtained from crossing the SHR and WKY Heidelberg
strains. The positive findings in the F2 progeny were also
supported by the semi-quantitative Western blot analyses
showing high Ephx2 gene expression in the renal cortex of
the parental WKY (Heidelberg) but not in SHR (Heidelberg).
Overall, a strong association exists between gene sequence,
protein abundance, and enzyme activity, apart from the
hypertensive state.
Later in this study, when the SHR and WKY rats from
Charles River were administered an sEHI, a small drop in
blood pressure was observed in both groups. However, the
absence of a dramatic reduction in blood pressure with an
sEHI in SHRs was inconsistent with previous reports
obtained with tail cuff measurements in SHRs. In the end,
this study shows that it is very crucial to know the genotype
of the animals studied and whether they carry the ancestral
or variant Ephx2 alleles in the research of sEH and
hypertension. Although the authors consider other possible
allelic influences, their observation in the F2 progeny
showing that there is no association between the inherited
Ephx2 alleles and blood pressure contrasts with previous
reports on the role of sEH in hypertension.
The association between sEH gene (Ephx2) polymor-
phisms and cardiovascular diseases has also been evaluated
in humans. sEH gene is located on chromosome 8p21-p12,
enclosing 19 exons. The polymorphisms in CYP2J2, a
major CYP450 enzyme generating EETs from AA in the
vasculature, are associated with low levels of EETs and an
increased risk of coronary artery disease [27]. In another
study investigating the role of Ephx2 polymorphisms in
atherosclerosis in African Americans and whites from the
Coronary Artery Risk Development in young Adults
(CARDIA) study of 18- to 30-year olds, where coronary
artery plaque calcification (CAC) measured by tomography
was used as a noninvasive indicator of atherosclerosis,
several gene polymorphisms have been identified, some of
which change the activity and the stability of the sEH
enzyme [28]. The results of the CARDIA study showed
that the sEH gene polymorphisms associated with CAC
correlate most highly among cigarette smokers, consistent
with previous findings that cigarette smoking upregulates
sEH in the vasculature [29]. The Atherosclerosis Risk in
Communities (ARIC) study, which includes15,792 men and
women 45–64 years of age, revealed 10 nonsynonymous
genetic variations in both the coding and noncoding regions
of Ephx2 gene [30]. Among those polymorphisms,
Lys55Arg (K55R) polymorphism in exon 2 has been found
to be an important risk factor for the development of
coronary heart disease (CHD) in whites with high frequency
(20.8%) compared with that in controls (15.3%). In
functional studies, K55R increases sEH activity, whereas
another common polymorphism, Arg287Gln (R287Q),
reduces sEH activity. Thus, the K55R polymorphism, in
both the heterozygous (A/G) and homozygous (G/G) states,
correlates with low ratio of plasma 12, 13- EpOME to
DiHOME, which provides a good in vivo biomarker of
increased sEH activity associated with K55R polymorphism
and CHD. This study also evaluated the significance of these
polymorphisms with reconstructed Ephx2 haplotypes and
the incidence of CHD. Indeed, the presence of six
haplotypes differed significantly between the CHD and
control cases, suggesting the importance of sEH gene
polymorphisms in cardiovascular diseases, and in particular
atherosclerosis. An association has also been found be-
tween the Ephx2 sequence variation, Glu287Arg, and
plasma cholesterol levels in familial hypercholesterolemia
using intra-familial correlation analysis [31].
In contrast to these studies, sEH mRNA transcript levels
were found to be five times lower leading to lower sEH
activity in the brain of stroke -prone SHRs rather than
stroke-resistant SHRs due to sequence variations in the sEH
gene promoter [32]. The low sEH activity did not result in
high levels of EETs in stroke-prone SHRs as would be
expected. When the gene expression of the P450 enzymes
synthesizing these epoxides were looked at, the data were
found to be consistent with EET levels, indicating differ-
ences in the mediators other than EETs in the mechanism of
the end organ injury. Although Ephx2 gene polymorphisms
have been shown to be associated with stroke, the allelic
differences in the Ephx2 in the SHRs did not predict blood
pressure levels [26]. Similarly, the study in stroke-prone
versus stroke-resistant SHRs revealed that the sequence
variations in the Ephx2 promoter somewhat relates to the
enzymatic activity, but fails to directly correlate these
polymorphisms with the risk for stroke in vivo due to the
complexity of the conditions [32]. A study in African
Americans also found no association between the epox-
ygenase gene SNPs (CYP2C8, 2C9, 2J2, and sEH) and
hypertension [33]. Thus, several studies suggest an associ-
ation among the enzymes that produce and degrade EETs
and cardiovascular disease; however, the association
appears complex.
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Although the human data demonstrate that the sEH (Ephx2)
gene polymorphisms are associated with increased risk for
atherosclerotic vascular diseases [30, 34–36], exploration of
the in vivo effects of sEH inhibition in animal models of
atherosclerosis only was reported recently. Ulu et al. [4••]
reported antiatherosclerotic effects of an sEH inhibitor using
anestablished murine model ofatherosclerosis in 5-month-old
apolipoprotein E (apoE)-deficient mice. In this model,
atherosclerosis development was accelerated in mice by
feeding the Paigen atherogenic diet and subcutaneously
infusing Ang II (1.44 mg/kg per day) for 4 weeks. An sEH
inhibitor, AEPU (1-adamantan-3-(5-(2-(2-ethylethoxy) eth-
oxy) pentyl) urea) (Fig. 2), was given in drinking water
(90 mg/L) for 8 weeks starting 4 weeks prior to the initiation
of atherogenic diet and Ang II and continued to the end of the
study. AEPU treatment reduced the atherosclerotic lesion area
in the descending aortas by 53% compared with that in
control mice treated with drinking water. The antiatheroscler-
otic effect of AEPU was accompanied by an inhibition of
sEH activity measured by a significant increase in linoleic
and AA epoxides, as well as the ratios of EETs to DHETs.
The reduction in the atherosclerotic lesion area was inversely
correlated with the ratios of 11, 12-EET/DHET and 14, 15-
EET/DHET, suggesting that the efficacy corresponds to the
inhibition of sEH.
In parallel, Wang and Cassis [37] reported more in-depth
observations in a similar model in which 6-month-old
apoE-deficient mice on normal rodent diet were infused
with Ang II (1.44 mg/kg per day) for 4 weeks to accelerate
atherosclerosis development and abdominal aortic aneu-
rysm formation. In addition, the left common carotid artery
was ligated at its bifurcation to induce vascular remodeling,
including neointima formation and adventitia development,
which resembles the pathogenesis of restenosis after
surgical angioplasty [38, 39•, 40, 41]. The mice had free
access to 5% hydroxypropyl-β-cyclodextrin in drinking
water containing an sEH inhibitor, AR9276 (1-(1-nicoti-
noylpiperidin-4-yl)-3-(4-(trifluoromethoxy) phenyl) urea) at
a concentration of 1.5 g/L for 4 weeks starting 1 day before
the Ang II infusion [3••]. Treatment with AR9276 com-
pletely abolished whole blood sEH activity measured by
monitoring the conversion rate of 14, 15-EET to 14, 15-
DHET. Treatment with AR9276 not only reduced athero-
sclerotic lesion area in the right carotid artery and aortic
arch by 33% and 39%, respectively, but also decreased the
incidence of abdominal aortic aneurysm formation by 72%
and the average diameters of abdominal aorta by 32%
compared with control mice drinking HPBCD water only
(Fig. 3). However, treatment of AR9276 did not affect
ligation-induced vascular remodeling in the right carotid
artery.
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Fig. 2 Representative structures of soluble epoxide hydrolase (sEH)
inhibitors. The most useful sEH inhibitors to date are competitive
transition state inhibitors of sEH [9, 11]. There are a variety of sEH
inhibitors available for use in animal models. The commercial
compounds such as AUDA are very potent, but hard to formulate
and rapidly metabolized. Increases in oral bioavailability and
improved physicochemical properties were obtained with AEPU and
APAU, with some loss of potency. Compounds such as TPPU and t-
TUCB have higher potency and much longer half-lives in vivo. The
potency of the piperidine compounds (APAU, TPPU) tends to be over-
estimated by roughly 20-fold compared with other inhibitors when a
common fluorescent assay is used. The Merck compound (Merck &
Co., Whitehouse Station, NJ) combines good potency and good rodent
pharmacokinetics [70]. Sorafenib is a commercial anti-cancer drug. Its
potency and pharmacokinetics indicate that it should inhibit the sEH
in humans at a fraction of the doses used therapeutically for cancer
[69]. A caution is that some but not all sEH inhibitors are active across
multiple species. For example, the activity of the piperidines (APAU,
TPPU) is often orders of magnitude lower in feline or canine models
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compelling evidence that sEH plays an important role in
the pathogenesis of atherosclerosis development and aneu-
rysm formation, suggesting that inhibition of sEH may be a
promising therapeutic intervention in these indications. The
exact mechanism by which sEH inhibitors exert therapeutic
benefits is still not clear, to which the following aspects
may contribute.
It has been established that elevation of circulating LDL
cholesterol and reduction of HDL play a causal role in
atherosclerosis development and progression [42]. Athero-
sclerotic lesions start with increased delivery and oxidation
of LDL cholesterol in the intima layer of the arterial wall
that initiates LDL uptake by monocytes and macrophages
to form foam cells, whereas HDL removes cholesterol from
the vascular wall. In addition, LDL tends to destabilize
platelet membrane activity and disrupt normal functions of
macrophages, endothelium, and VSMC, whereas HDL
tends to reverse these abnormalities [42]. An important
mechanism by which statins prevent atherosclerosis and
exert therapeutic effects in coronary artery disease is by
lowering LDL in conjunction with minor increase in HDL
[43]. The current clinical application of statins in combina-
tion with niacin to increase HDL levels has been shown
more effective than monotherapy. Zhang et al. [3••]
demonstrated that sEH inhibition lowered circulating LDL
by 30%, elevated HDL by 43%, and elevated the HDL to
LDL ratio by 96%, which could contribute, at least
partially, to the antiatherosclerotic effects of sEH inhibitors.
In sEH-deficient mice and sEH-expressing mammalian cell
lines, low cholesterol levels have been found. Farnesyl
phosphate and pyrophosphate are key intermediates in
steroid biosynthesis and prenylation and they are excellent
substrate for the phosphatase component of sEH. Thus, the
sEH phosphatase activity has been proposed as possibly
responsible for this effect [44]. In contrast to the lipid-
lowering effect of AR9276 reported by Zhang et al. [3••], in
the study by Ulu et al. [4••], AEPU did not affect blood
cholesterol levels. This discrepancy between the two labora-
tories could result from the use of different sEH inhibitors.
Alternatively,theuseofdifferentdietsorsourcesofanimalsin
the two studies may also impact the profile of responses.
Vascular inflammation characterized by infiltration of
monocytes/macrophages and lymphocytes into the arterial
wall is a crucial pathogenic event in atherosclerosis and
aneurysm formation [45–47]. Cholesterol accumulation and
oxidative LDL in the vascular wall lead to expression of
adhesion molecules and release of chemotactic factors. This
process triggers the release of cytokines and VSMC
migration. which secretes extracellular matrix metallopro-
teinases, resulting in chronic inflammation [48]. Moreover,
Ang II is not only a vasoconstrictor, but it also is a
proinflammatory factor that promotes atherosclerosis de-
velopment and vascular remodeling via stimulating proin-
flammatory factors in vascular endothelium. including
vascular adhesion molecule, chemokines, cytokines, and
growth factors that further facilitate monocyte/macrophage
and T-cell infiltration and VSMC migration into the
subendothelial space [49–51]. Ang II is also a potent
inducer of the she. which may account for some of its
inflammatory actions [7, 21]. These inflammatory cells take
up lipids, becoming foam cells that coalesce into athero-
sclerotic lesions [52]. Tedgui and Mallat [53] demonstrated
that treatment with AR9276 reduced serum inflammatory
markers, including interleukin (IL)-1α, IL-6, and KC, and
murine IL-8, all of which were reported to be involved in
the progression of atherosclerosis. In agreement with this,
Fang et al. [54, 55] reported that sEH inhibition increased
10, 11-epoxy-16:2 generation from 14, 15-EET, which not
only inhibited tumor necrosis factor (TNF)-α–mediated
Atherosclerotic Lesions
Aorta Carotid  A.
Abdominal Aortic 
Aneurysm
A
R
9
2
7
6
 
 
V
e
h
i
c
l
e
1 mm
Fig. 3 Treatment of a soluble epoxide hydrolase (sEH) inhibitor
reduces atherosclerotic lesions in the aorta (left) and carotid artery
(middle) and attenuates abdominal aortic aneurysm formation (right)
in apolipoprotein E–deficient mice. An sEH inhibitor, AR9276, was
administrated in drinking water (1.5 g/L) for 4 weeks in apolipopro-
tein E–deficient mice (6-months of age) chronically infused with
angiotensin II (1.44 mg/kg per day) to accelerate atherosclerosis
development and induce abdominal aneurysm formation
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coronary endothelial cells, but also enhanced dilation of
coronary microvessels [54, 55]. This observation raises the
possibility that epoxides of a variety of fatty acids,
including chain lengthened and shortened metabolites of
AA, omega-3 lipids and other fatty acids, and epoxides
from COX and LOX products, may both be biologically
active and stabilized by sEHI. Indeed, Galkina and Ley [56]
further showed that treatment with AR9276 decreased
proinflammatory gene expression in the arterial wall,
especially vascular cell adhesion molecule-1 (VCAM-1)
and intercellular adhesion molecule-1 (ICAM-1), which are
critical in initiation and development of atherosclerosis.
Furthermore, direct application of EETs in human endothe-
lial cells inhibited TNF-α–induced VCAM-1 and ICAM-1
expression [10]. Taken together, these data support the
concept that anti-inflammatory effects may be another
important mechanism by which sEH inhibitor attenuates
Ang II–accelerated atherosclerosis and aneurysm formation.
High blood pressure can cause vascular injury, thereby,
facilitating the development of atherosclerosis. It has been
established that treatment with sEH inhibitors reduces
blood pressure in several animal models of hypertension
[7, 14, 15]. Thus, blood pressure reduction can also
contribute to the antiatherosclerotic effects of sEH inhib-
itors. One of the important functions of endothelium is to
protect the vessel from injury. EETs are generated from
endothelium and play a critical role in regulation of
endothelial-derived vascular function. Endothelial dysfunc-
tion, manifest as impaired endothelium-dependent vaso-
relaxation, is a hallmark of, and plays a pivotal role in,
pathogenesis of cardiometabolic diseases, including athero-
sclerosis, type 2 diabetes, obesity, and hypertension.
Multiple studies show that treatment with sEHIs improves
endothelial functions in a number of animal models of
hypertension, obesity, and diabetes [3••]. Thus, improve-
ment of endothelial function can also contribute to the
antiatherosclerotic effects of sEH inhibitors.
Smooth muscle cell migration and proliferation are some
of the major pathologic processes evident in the Ang II–
accelerated vascular remodeling in the carotid artery
ligation model [39, 41]. EETs have been shown to attenuate
the migration of VSMC stimulated with platelet-derived
growth factor in rat aortas [57]. Recently, Davis et al. [58,
59] reported that sEH inhibitors attenuated VSMC prolif-
eration; however, they later showed that this effect is
compound chemical-structure specific and independent of
sEH inhibition. Consistent with the latter report, Simpkins
et al. [60] observed that treatment with AR9276 had no
effect on ligation-induced vascular remodeling. Further-
more, a very recent article reported that sEH inhibition or
Ephx2 gene deletion antagonizes neointimal formation in
vivo by mechanisms that are endothelium dependent [60].
In contrast, Kullmann et al. [61] reported that the Ephx2
K55R polymorphism is not associated with restenosis after
percutaneous coronary intervention in human. Taken
together, it appears that the effects of sEH inhibition on
VSMC proliferation and migration and on neointimal
formation after vascular injury are controversial.
Conclusions
The preclinical observations of the beneficial effects of
EETs and sEH inhibitors, including vasodilation, antihy-
pertension, antiinflammation, improving endothelial func-
tion, and lipid regulation, along with the clinical
observation of an association of the sEH (Ephx2) gene
polymorphisms with increased risks of atherosclerotic
vascular disease, provide a strong rationale to target sEH
in the treatment of atherosclerosis. In support of this
rationale are the observations that treatment with sEH
inhibitors in apoE-deficient mice significantly attenuated
atherosclerosis development and aneurysm formation. The
pathogenesis of atherosclerosis is complex, involving
multiple mechanisms. Although translation of preclinical
efficacy in animal models to human disease remains to be
demonstrated in clinical trials, the numerous positive effects
of sEHI in cardiovascular diseases render the sEH a
promising therapeutic target [13, 62••].
In addition to monotherapy, sEH inhibitors may also be
combined with other existing drugs for atherosclerotic
vascular disease. Even though the current antiatheroscler-
otic therapy is effective in reducing cholesterol and
cardiovascular risk, it targets the disease beyond the
underlying processes. For example, atorvastatin possesses
anti-inflammatory properties similar to 15-epi-lipoxin A4
(15-epi- LXA4), which resides in the lipoxygenase branch
of the AA cascade and acts to resolve inflammation [63,
64]. Lovastatin has been shown to reduce acute mucosal
inflammation in polymorphonuclear leukocytes and airway
epithelial cells by a mechanism involving the generation of
15-epi-LXA4 and 14, 15- EET [65]. At the cellular level,
14, 15- EET has been shown to induce the generation of
15- epi- LXA in this study. Given these data, an advanced
therapy to reduce the underlying causes of atherosclerosis
such as inflammation, by using both a statin and a sEH
inhibitor to reduce cholesterol and induce anti-inflammation
via EETs and 15-epi-LXA4, remains to be elucidated.
Furthermore, aspirin, nonsteroidal anti-inflammatory drugs,
and LOX5 inhibitors have been shown to synergize
dramatically with sEHI in several indications, including
inflammation [20, 66]. This synergy might be applicable to
treating atherosclerosis. sEHI and peroxisome proliferator–
activated receptor (PPAR)-based drugs are also synergistic
when used preclinically as a combination therapy [67].
180 Curr Atheroscler Rep (2010) 12:174–183Drugs targeting inflammation and other mechanisms
underlying atherosclerosis, such as VSMC proliferation and
migration,endothelialdysfunction, and activationof adhesion
molecules, offer promise in prevention and treatment of
atherosclerosis and in reduction of cardiac events. The
combination of sEHI with existing therapies may synergisti-
cally enhance the lipid lowering, anti-inflammatory, and
antihypertensive benefits, or may reduce the adverse effects
by lowering the doses of existing drugs. The broad spectrum
of sEH inhibitors with multiple biological beneficial actions
provides a promising new class of therapeutics for atheroscle-
rosis and other cardiovascular diseases.
However, the broad spectrum of biological activities
of EETs may render concerns of potential undesired
effects for sEHIs. For example, EETs have been reported
to promote angiogenesis via growth factors and cell
signaling mechanisms involving Janus-activated STAT
signaling [68]. Such angiogenic effects may lead to
metastasis in various types of cancers. In contrast, the
angiogenesis is beneficial in promoting wound healing.
and tissue repair. Thus, the exact impact of sEH inhibitors
on therapeutic benefits versus potential adverse effects
remains to be examined.
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